Get the Stockscreener App
1.6399
4.14%
0.0699
Telomir Pharmaceuticals Inc stock is traded at $1.6399, with a volume of 323.46K.
It is up +4.14% in the last 24 hours and up +6.86% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.57
Open:
$1.58
24h Volume:
323.46K
Relative Volume:
0.07
Market Cap:
$52.78M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-3.0369
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
+2.19%
1M Performance:
+6.86%
6M Performance:
-34.07%
1Y Performance:
-65.21%
1-Day Range:
$1.575
$1.64
1-Week Range:
$1.52
$1.75
52-Week Range:
$1.12
$7.0791
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.635 | 53.11M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.42 | 106.87B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
493.38 | 63.14B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.77 | 61.27B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
853.07 | 51.94B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
167.43 | 35.04B | 398.11M | -1.03B | -868.57M | -5.7032 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Momentum divergence signals in Telomir Pharmaceuticals Inc. chartQuarterly Profit Review & Target Return Focused Stock Picks - newser.com
Telomir Pharmaceuticals Inc. stock chart pattern explainedOptions Play & Step-by-Step Trade Execution Guides - newser.com
Does Telomir Pharmaceuticals Inc. show high probability of rebound2025 Analyst Calls & Long-Term Safe Investment Plans - newser.com
Combining price and volume data for Telomir Pharmaceuticals Inc.Weekly Loss Report & High Return Stock Watch Alerts - newser.com
Why Telomir Pharmaceuticals Inc. is moving todayEarnings Beat & Weekly High Conviction Trade Ideas - newser.com
How moving averages guide Telomir Pharmaceuticals Inc. tradingIPO Watch & Free Fast Gain Swing Trade Alerts - newser.com
Bearish Setup: Can Acurx Pharmaceuticals Inc. stock withstand economic slowdown2025 Big Picture & Expert Curated Trade Setup Alerts - Trung tâm Dự báo KTTV quốc gia
Chart Watch: Will Telomir Pharmaceuticals Inc. stock benefit from AI adoptionJuly 2025 PostEarnings & Stepwise Trade Signal Guides - nchmf.gov.vn
What dividend safety score for Telomir Pharmaceuticals Inc. stockQuarterly Profit Review & Reliable Volume Spike Alerts - Trung tâm Dự báo KTTV quốc gia
Is Telomir Pharmaceuticals Inc. stock a buy on dips2025 Winners & Losers & Long-Term Growth Portfolio Plans - nchmf.gov.vn
Will Telomir Pharmaceuticals Inc. stock maintain momentum in 2025Gap Down & Real-Time Chart Pattern Alerts - nchmf.gov.vn
FOMO Trade: Will Telomir Pharmaceuticals Inc. stock benefit from AI adoption2025 Key Lessons & Expert-Curated Trade Recommendations - nchmf.gov.vn
Can Telomir Pharmaceuticals Inc. stock withstand economic slowdownQuarterly Profit Report & Real-Time Volume Spike Alerts - nchmf.gov.vn
Swing Trade: Is Telomir Pharmaceuticals Inc. stock cheap at current valuationPortfolio Performance Summary & Low Risk High Reward Ideas - nchmf.gov.vn
Is Telomir Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Highlights & Weekly High Return Forecasts - nchmf.gov.vn
Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results - MSN
Tools to assess Telomir Pharmaceuticals Inc.’s risk profilePortfolio Value Report & Daily Stock Momentum Reports - newser.com
What to do if you’re stuck in Telomir Pharmaceuticals Inc.2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Telomir Pharmaceuticals Inc. stock outlook for YEARJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
How Telomir Pharmaceuticals Inc. stock performs in high volatility marketsQuarterly Portfolio Review & Precise Trade Entry Recommendations - newser.com
Custom watchlist performance reports with Telomir Pharmaceuticals Inc.July 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer - Palm Beach Daily News
Telomir-1 shows efficacy against pancreatic cancer cells in lab study - Investing.com Canada
Telomir Pharmaceuticals, Inc. Announces New Laboratory Findings Demonstrating That Telomir-1 Reduced the Survival of Aggressive Human Pancreatic Cancer Cells in Vitro - MarketScreener
Telomir-1 shows efficacy against pancreatic cancer cells in lab study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Unveils Promising Pancreatic Cancer Findings - TipRanks
Kills aggressive pancreatic cancer cells — Telomir‑1 reduces PANC‑1 survival; partial reversal with iron in preclinical study - Stock Titan
Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer - Investing.com
Telomir Pharmaceuticals Announces New Data on Telomir-1's Impact on Pancreatic Cancer - TradingView
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):